Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...

The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the ...

A Belgian court dismissed a lawsuit against EU chief Ursula von der Leyen centered on text messages she exchanged with Pfizer ...

Pharmaceutical stocks can bring an element of safety to your portfolio. All of this equals a rather steady stream of revenue ...

Karen Robinovitz and Sara Schiller bonded over slime — and turned a TikTok-fueled craze into a profitable business with ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Pfizer’s CEO stated that the company revamped its commercial strategy, brought in new leadership, and exceeded market share expectations. On the cost side, Pfizer achieved $4 billion in savings ...

Pfizer (PFE) announces that it intends to sell approximately 700M ordinary shares in Haleon plc (HLN), representing approximately 7.7% of Haleon’s issued share capital. “There will be no sale ...

In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck laid out their plans to overcome high-profile losses of exclusivity (LOEs) slated to dent sales through the end of the ...